Cash Stream from Licensing Deal to Help Biopharma Advance Lead Drug
August 01, 2018 at 04:00 AM EDT
Source: Streetwise Reports 08/01/2018 A Laidlaw & Co. report discussed this firm’s revenue and near-term, clinical catalysts. In a July 30 research note, analyst Francois Brisebois with Laidlaw & Co. reported that DURECT Corp. (DRRX:NASDAQ) [...]
